A Novel Synergistic Approach
Lipidose™ + Antibiotics - The Future of Gram-Negative Infection Management
Lipidose™ is a groundbreaking therapeutic agent that specifically binds and neutralizes bacterial endotoxin (LPS), which is released during gram-negative bacterial infections. By complementing antibiotic therapy, Lipidose™ significantly reduces inflammation and sepsis risk through its unique dual mechanism of action: enhancing HDL capacity to clear endotoxin and blocking the TLR4 pathway that triggers inflammatory cascades. This synergistic approach addresses both the infection and its toxic consequences simultaneously, providing a comprehensive solution for managing severe gram-negative infections.
12-25%
in Catheter-Related Bloodstream Infections
$25,000-$45,000
Average savings per patient
2-4 Days
Shorter intensive care duration
Until 2032+
Strategy to extend to 2040+
Gram-negative bacterial infections release massive amounts of lipopolysaccharide (LPS), triggering dangerous inflammatory cascades that can lead to septic shock and multi-organ failure.
Lipidose™ specifically binds and neutralizes LPS before it can escalate into sepsis, providing critical protection during the vulnerable period of antibiotic treatment.
Unlike any treatment on the market, Lipidose™ works synergistically with antibiotics, addressing both the infection and its toxic inflammatory consequences simultaneously.